Cargando…
Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?
BACKGROUND: To evaluate health-related quality of life (HRQL) and medication satisfaction after switching from a stable dose of oral extended-release methylphenidate (ER-MPH) to methylphenidate transdermal system (MTS) via a dose-transition schedule in children with attention-deficit/hyperactivity d...
Autores principales: | Bukstein, Oscar G, Arnold, L Eugene, Landgraf, Jeanne M, Hodgkins, Paul |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2796990/ https://www.ncbi.nlm.nih.gov/pubmed/20003260 http://dx.doi.org/10.1186/1753-2000-3-39 |
Ejemplares similares
-
Transdermal Therapy for Attention-Deficit Hyperactivity Disorder with the Methylphenidate Patch (MTS)
por: Findling, Robert L., et al.
Publicado: (2014) -
Methylphenidate Transdermal System in Attention-Deficit Hyperactivity Disorder in Adolescentsy: Profile Report
por: Keating, Gillian M.
Publicado: (2012) -
Cost-Effectiveness of Extended-Release Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder Sub-Optimally Treated with Immediate Release Methylphenidate
por: van der Schans, Jurjen, et al.
Publicado: (2015) -
Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options
por: Hodgkins, Paul, et al.
Publicado: (2012) -
Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder
por: Pliszka, Steven R., et al.
Publicado: (2017)